1. Generics Bulletin
  2. >>Business
  3. >>Deals

Ligand Set For Partnership Opportunities After Completing On Pfenex

Sets Out Strategy And Revenue Drivers After Finalizing $500m Deal

 
• By Dave Wallace

Fresh from completing its acquisition of Pfenex, Ligand Pharmaceuticals has laid out the benefits that it expects to gain from the deal.

Open doors
The Pfenex deal opens the door to at least three new partnerships in the next 12 months, Ligand says • Source: Shutterstock

Ligand Pharmaceuticals expects to strike at least three new partnership deals over the coming year thanks to its acquisition of Pfenex, which the biopharma company has just completed.

Specializing in “developing or acquiring technologies that help pharmaceutical companies discover and develop medicines,” Ligand earlier this year struck a deal valued at up to $516m to acquire Pfenex, pointing in particular to the attraction of the firm’s proprietary Pfenex Expression Technology

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By Dave Wallace

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By Dean Rudge

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.